|
|
           
|
|
|
|
|
|
|
|
 
|
|
Rv1483 More about Rv1483 on TBDB.org More about Rv1483 on TubercuList |
Display all mutations or select a bar from the histogram above to examine in greater detail |
| Rv1483: all mutations (high confidence mutations are highlighted in yellow) | |||||||||||||||
| Primary reference | Polymorphism | Nucleotide position | Codon position | Amino acid | Time period | Origin | Molecular detection method | Gene coverage | Resistance pattern | MIC | Susceptibility testing method | R/Total isolates | R/S isolates with mutation | Additional mutations | High confidence support |
| Ramaswamy SV AAC 2003 | G/T | -147 | -147 | - | - | - | - | - | - | - | - | - | - | - | - |
| Lee ASG AAC 1999 | A/T | -92 | -92 | - | 1994-1996 | Singapore | Sequencing | Promoter region of inhA | H | 0.1ug/ml | BACTEC 460 | 160/192 | 1/0 | katG or ahpC-oxyR mut | - |
| Doustdar F MDR 2008 | G/C | -67 | -67 | - | 2005-2006 | Iran | Sequencing | 250bp around 315 and 212 bp around 463, 238bp of inhA and 293bp of ahpC | H | N.S. | Proportion method | 48/93 | 1/0 | inhA 40 G/C and ahpC -6 G/A | - |
| Rindi L Int J Tuberc Lung Dis 2005 | G/T | -24 | -24 | - | 1994-2002 | Italy | Sequencing | nt 56-303 | - | - | - | 45/45 | 1/0 | not mentioned | - |
| Rouse DA AAC 1995 | G/T | -24 | -24 | - | 1995 | - | PCR SSCP analysis, | N.S. | HS | 0.2ug/ml I, 4ug/mlS | Absolute concentration method | 26/26 | 1/0 | R463l katG | - |
| Baker LV AAC 2005 | G/T | -24 | -24 | - | 1998 | United Kingdom | Directed Oligonucleotide array, Sequencing | inhA promoter region | H,HS,HE,HSE,MDR | ratio>=4 | Resistance ratio method | 202/378 | 1/0 | S315T Arg463Leu in katG, -46G/A in oxyRahpc intergenic region | - |
| Morlock GP AAC 2003 | G/T | -17 | -17 | - | 2003 | USA | Sequencing | 284 bp of inhA promoter and nt 13-379 of inhA | HEth | 100ug/ml E, 8 ug/ml I | Proportion method | 41/42 | 1/0 | I21T inhA ORF | - |
| Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998 | A/G | -16 | -16 | - | - | - | - | - | - | - | - | - | - | - | - |
| Lee ASG AAC 1999 | C/T | -15 | -15 | - | 1994-1996 | Singapore | Sequencing | Promoter region of inhA | H | 0.1UG/ML | BACTEC 460 radimetric method | 160/192 | 43/0 | katG or ahpC-oxyR mut |  |
| Secondary Publication: Hazbon MH AAC 2006 | A/T | -11 | -11 | - | - | - | - | - | - | - | - | - | - | - | - |
| Lee ASG AAC 1999 | T/A | -8 | -8 | - | 1994-1996 | Singapore | Sequencing | Promoter region of inhA | H | 0.1UG/ML | BACTEC 460 radimetric method | 160/192 | 1/0 | katG or ahpC-oxyR mut | |
| Baker LV AAC 2005 | T/C | -8 | -8 | - | 1998 | United Kingdom | Directed Oligonucleotide array, Sequencing | Promoter region of inhA | H,HS,HE,HSE,MDR | ratio>=4 | Resistance ratio method | 202/378 | 1/0 | none | |
| Rouse DA AAC 1995 | T/G | -8 | -8 | - | 1995 | - | PCR SSCP analysis | not specified | H | 0.2ug/ml | Absolute concentration method | 39990 | 1/0 | none | - |
| Sekigushi J JCM 2007 | T/A | -5 | -5 | - | 2007 | - | Sequencing | nt-217 to -198, 1145-1126 | - | - | Proportion method, BACTEC | 38/138 | 1/0 | M257T R463L katG | - |
| Doustdar F MDR 2008 | GCC/CCC | 13 | 5 | Ala/Pro | 2005-2006 | Iran | Sequencing | 250bp around 315 and 212 bp around 463, 238bp of inhA and 293bp of ahpC | H | N.S. | Proportion method | 48/93 | 1/0 | mabA -15 C/T and ahpC -6 G/A | - |
| Doustdar F MDR 2008 | GTA/CTA | 40 | 14 | Val/Leu | 2005-2006 | Iran | Sequencing | 250bp around 315 and 212 bp around 463, 238bp of inhA and 293bp of ahpC | H | N.S. | Proportion method | 48/93 | 1/0 | mabA -67 G/C and ahpC -6 G/A | - |
| Secondary Publication: Hazbon MH AAC 2006 | ACC/GCC | 61 | 21 | Thr/Ala | - | - | - | - | - | - | - | - | - | - | - |
Disclaimer: These are all putative mutations found in drug resistant clinical TB isolates. No a priori decisions have been made as to whether these mutations are causally related to resistance or possible secondary mutations. |
|
© 2010 Andreas Sandgren | Supported by the Swedish Research Council | Contact Database Curator |